Article

AXL mediates mast cell survival and resistance to tyrosine kinase inhibitors in mastocytosis

2025-11-04

Abstract excerpt

Mastocytosis is a clonal disorder driven by KIT mutations, but resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge. Following the discovery of an AXL L197M mutation in a patient with congenital aggressive mastocytosis, we demonstrated unexpected wild-type AXL expression in neoplastic mast cells (MCs) across mastocytosis subtypes, challenging current views concerning mastocytosis pathophysio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f8c3493d-d010-58b8-a686-52169ffb3635
DOI: 10.1101/2025.11.03.686205

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AXL mediates mast cell survival and resistance to tyrosine kinase inhibitors in mastocytosisDOI 10.1101/2025.11.03.686205Read

Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.Semantic proximity Read

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.Semantic proximity Read

Recent advances in the understanding and therapeutic management of mastocytosisSemantic proximity Read

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.Semantic proximity Read

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Semantic proximity Read

Precision Medicine in Systemic Mastocytosis.Semantic proximity Read

Mast Cell Leukemia: An Update with a Practical ReviewSemantic proximity Read

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.Semantic proximity Read

New Insights into the Pathogenesis of Systemic Mastocytosis.Semantic proximity Read

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.Semantic proximity Read

Molecular defects in mastocytosis: KIT and beyond KIT.Semantic proximity Read

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.Semantic proximity Read